Latest Breaking News On - Frank neumann - Page 4 : comparemela.com

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy® in Metastatic Breast Cancers – – New Data Demonstrate Potential of Trodelvy in Small Cell Lung Cancer,.

Foster cityUnited statesComunidad autonoma de catalunaCastillay leópFrank neumannSanta monicaEnfortumab vedotinAxicabtagene ciloleucelGilead sciences incEuropean unionExchange commissionEuropean society for medical oncologyGilead sciencesGilead companyGlobal head of clinical developmentGilead public affairs

Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma

Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.

Frank neumannDavida litmanRoch houotKite global head of clinical developmentHaematology departmentUniversity hospital of rennesUniversity hospitalGlobal headClinical development

Kite s Car T-cell Therapy Yescarta Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed, Refractory Large B-cell Lymphoma

SANTA MONICA - Kite, a Gilead Company , today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen.

Santa monicaUnited statesFoster cityJacquie rossFrank neumannRoch houotGilead sciences incCollaborative groupUniversity hospital of rennesLymphoma study associationGilead companyGilead sciencesExchange commissionGilead company nasdaqKite global head of clinical developmentHaematology department

CAR T therapy Yescarta shows promising proficiency in R/R LBCL

CAR T therapy Yescarta shows promising proficiency in R/R LBCL
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Frank neumannRoch houotGilead companyKite global head of clinical developmentProfessor roch houotHaematology departmentUniversity hospitalGlobal headClinical development

Kite s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

– Yescarta Achieved a Complete Metabolic Response of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls – – Results Published in Nature Medicine– .

United statesSanta monicaFoster cityFrank neumannRoch houotGilead sciences incLymphoma study associationCollaborative groupGilead company nasdaqGilead companyKite global head of clinical developmentLymphoma academic research organizationHead of haematology departmentUniversity hospital of rennesExchange commissionGilead sciences